JY. Cui1, CJ. Li2, QY. Li2, YF. Xia2, JJ. Zhao3 and YL. Zhang4

Author information

1Department of Hematology, Weifang People’s Hospital, Weifang, China;
2Department of Imaging, Zhangqiu District People’s Hospital, Jinan, China;
3Department of Surgery, Zhangqiu District People’s Hospital, Jinan, China;
4Department of Hematology, Zhangqiu District People’s Hospital, Jinan, China

Abstract

The purpose of the study was to investigate the clinical therapeutic effect of decitabine combined with chidamide based on coronal angiography (CAG) regimen on acute myelogenous leukemia (AML). A total of 90 AML patients admitted to our hospital from February 2016 to February 2017 were selected as the study subjects and randomly divided into control group (n=45) and experimental group (n=45). Among them, the patients in the control group were treated with decitabine combined with chidamide, while based on the treatment in the control group the patients in the experimental group received CAG regimen. After that, the clinical overall remission rate, the incidence of adverse reactions as well as the proportion of myeloblasts in bone marrow were all compared between the two groups. The clinical overall remission rate of 82.22% in the experimental group was significantly higher than that of 62.22% in the control group (P <0.05), the incidence of adverse reactions of 73.33% in the experimental group was significantly lower than that of 91.11% in the control group (P <0.05), and the proportion of myeloblasts in bone marrow in the experimental group was significantly lower than that in the control group (P<0.001). The implementation of decitabine combined with chidamide based on CAG regimen in AML patients can improve the therapeutic effect and enhance the immune function of cells, with obvious curative effect, which is worthy of application and promotion in the clinical practice.

Key words:

CAG regimen, decitabine, chidamide, acute myelogenous leukemia

Copyright 2021 Biolife Sas. www.biolifesas.org